2D Biomedical Hyperspectral Imager - Phase II

Information

  • Research Project
  • 7327401
  • ApplicationId
    7327401
  • Core Project Number
    R44EY016277
  • Full Project Number
    2R44EY016277-02
  • Serial Number
    16277
  • FOA Number
    PA-06-20
  • Sub Project Id
  • Project Start Date
    9/30/2005 - 19 years ago
  • Project End Date
    8/31/2009 - 15 years ago
  • Program Officer Name
    WUJEK, JEROME R
  • Budget Start Date
    9/30/2007 - 17 years ago
  • Budget End Date
    8/31/2008 - 16 years ago
  • Fiscal Year
    2007
  • Support Year
    2
  • Suffix
  • Award Notice Date
    9/21/2007 - 17 years ago
Organizations

2D Biomedical Hyperspectral Imager - Phase II

[unreadable] DESCRIPTION (provided by applicant): This proposal from KESTREL CORPORATION continues the research work on a new three dimensional (two spatial, one spectral) hyperspectral imager for use in clinical and biomedical research applications. Kestrel's three dimensional hyperspectral retinal imager concept merges two developing technologies, Fourier Transform hyperspectral imaging technology and Integral Field Spectroscopy. The two technologies allow an imaged region to be spatially sampled in a two dimensional area while retaining the spectral information in each sample. These samples are then processed and reassembled to create a full three dimensional hyperspectral data cube containing two spatial dimensions with full spectral content of the selected area. In Phase 1 Kestrel successfully demonstrated the feasibility of the proposed technology. Phase 2 builds on this success by implementing a prototype of a new retinal imager that can be used to advance the knowledge the mechanisms of retinal diseases and the clinical practice to manage such illnesses. The Specific Aims of this proposal are: Aim 1. Address the effects of fabrication of the Integral Field Unit on the spectral data. Aim 2. Obtain the optimum configuration of the Integral Field Unit for medical applications. Aim 3. Build a prototype of a new kind of fundus imager that can collect complete hyperspectral data cubes in single exposures. Aim 4. Collect a comprehensive database of spectral signatures of retinal features from normal subjects and subjects presenting different degrees of diabetic retinopathy and age-related macular degeneration. Aim 5. Demonstrate the clinical value of spectral imaging of the retina by determining features in the spectral information that correlate with the current assessment of retinal health status. Applications for this technology exist across a wide range of biomedical imaging. The value of hyperspectral medical imaging and especially its application in ocular uses is slowly gaining recognition. However, the current implementation of these hyperspectral devices limits their transition to wide spread clinical and research in vivo uses because of the techniques employed in collecting a three dimensional data cube are for practical purposes unusable. The technology proposed offers the potential of overcoming this limitation. [unreadable] [unreadable] [unreadable]

IC Name
NATIONAL EYE INSTITUTE
  • Activity
    R44
  • Administering IC
    EY
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    439438
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    389
  • Ed Inst. Type
  • Funding ICs
    NCRR:439438\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    KESTREL CORPORATION
  • Organization Department
  • Organization DUNS
    807812870
  • Organization City
    ALBUQUERQUE
  • Organization State
    NM
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    87109
  • Organization District
    UNITED STATES